Resources

2 Resources for

biopharmaceutical

Subscribe to this listing via:
RSS
Email

Did you mean Omrix Biopharmaceuticals Inc. (5 results), nabi biopharmaceuticals (3 results), keryx biopharmaceuticals inc. (2 results)

BNET Resources

Biotech's New Blockbusters -- Oh, Really?: Biotech's New Blockbusters -- Oh, Really?20 to 30 Blockbusters of Biotech Exist NowInnovation in Pharmacology?Beginning in the 1970, biopharmaceuticals were being researched for conceptual production in those places once called academic institutions. The first biopharmaceutical ever was a synthetic insulin called Humulin made by Genetech in 1982. Later...; Tags: BioPharma, biopharmaceutical, biotechnology, patient, pharmaceutical company; Discussion threads 2008-07-10
Catalogue release. (Market focus: USA: an overview of the latest products and services from a selection of US companies).: Millipore has released two catalogues featuring its tools, technologies and services. The 2002-2003 Biopharmaceutical catalogue highlights its filtration, purification and viral clearance selection tools and an expanded line of quality control ... Millipore has released two catalogues featuring its tools, technologies and services....; Tags: Biopharmaceutical, Millipore Corp.; Research articles 2002-09-01

Additional Resources

Protherics PLC - Approved Share Option Scheme: Protherics PLC 6 monthly Block Listing Return Approved Share Option SchemeLondon,...; Articles 2008-10-09
Protherics PLC - Unapproved Share Option Scheme: Protherics PLC 6 monthly Block Listing Return Unapproved Share Option SchemeLondon, UK; Brentwood, TN;...; Articles 2008-10-09
Protherics PLC Announces SAYE Blocklisting: Protherics PLC6 monthly Block Listing ReturnSavings Related Share Option SchemeLondon, UK; Brentwood, TN; 9 October 2008 - Protherics PLC("Protherics" or the "Company"), the international biopharmaceuticalcompany focused on critical care and cancer, in accordance with ListingRule 3.5.6, notifies the following details in respect of the blocklisting for its 1998 Savings Related...; Articles 2008-10-09

Protherics PLC Announces Individual Blocklisting: Protherics PLC6 monthly Block Listing ReturnIndividual Unapproved Share OptionsLondon, UK; Brentwood, TN; 9 October 2008 - Protherics PLC("Protherics" or the "Company"), the international biopharmaceuticalcompany focused on critical care and cancer, in accordance with ListingRule 3.5.6, notifies the following details in respect of the blocklisting for its Individual Unapproved share option...; Articles 2008-10-09
BellwetherReport.com Analyst Opinions on AFL, TSFG, OMRI and SSCC: BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...; Articles 2008-10-09
Lorus Therapeutics Reports First Quarter Results for Fiscal Year 2009: Lorus Therapeutics Inc. Lorus (TSX: LOR)(AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three months ended August 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars. JUNE 1, 2008...; Articles 2008-10-09
CytRx Corporation to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference: LOS ANGELES -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that David Haen, CytRx Vice President of Business Development, will present a corporate overview of the Company at the Natixis Bleichroeder Second Annual Hidden Gems Conference at the Waldorf...; Articles 2008-10-08
Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials: NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today interim results from its U.S. Phase II clinical trial evaluating the safety and hemostatic effectiveness of the Company's Fibrin Pad product candidate as an adjunct to control...; Articles 2008-10-08
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer: SEATTLE -- Calistoga Pharmaceuticals, Inc., a company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, today announced the appointment of Carol G. Gallagher, Pharm. D., as Chief Executive Officer. With previous leadership roles at both large and small biopharmaceutical companies, Dr. Gallagher brings expertise in...; Articles 2008-10-08
Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds: LONDON, Oct. 7 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced today the results of the ongoing screening of its novel anti-inflammatory drugs using MD Biosciences' ImmunoprofilerTM in vitro screening service. The screen was specifically chosen to identify and assess...; Articles 2008-10-07
Huifeng Bio-Pharmaceutical Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit: XI'AN, China, Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB; the "Company"), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in Xi'an, China, is pleased to announce the signing of a formal exclusive...; Articles 2008-10-07
Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City: SAN CARLOS, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics President and CEO Howard W. Robin is scheduled to present at the upcoming Natixis Bleichroeder Second Annual Hidden Gems Conference in New York at the Waldorf-Astoria Hotel on Monday, October 13, 2008 at 2:30 p.m. ET. The...; Articles 2008-10-07
ReadSoft AB wins USD350,000 invoice automation order from US biopharmaceutical company: NORDIC BUSINESS REPORT-7 October 2008-ReadSoft AB wins USD350,000 invoice automation order from US biopharmaceutical companyC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish document automation solutions provider ReadSoft AB (OMX Stockholm:RSOF B) said on Tuesday (7 October) that it has received a USD350,000 order from a US biopharmaceutical company. ...; Articles 2008-10-07
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial: - Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen of Bavituximab in Combination With Carboplatin and Paclitaxel - TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis...; Articles 2008-10-07
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE® Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD: In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced that a study published in the September issue of the Journal of Clinical Psychiatry...; Articles 2008-10-07
XTL Biopharmaceuticals Announces Completion of the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain: VALLEY COTTAGE, New York, Oct. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that the last patient randomized into the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain has completed the study. This milestone officially marks the completion of this randomized, double-blind, placebo-controlled...; Articles 2008-10-07
Millipore Opens New Manufacturing Facility in Ireland: Official ceremony also marks company's 20 years in Cork BILLERICA, Mass. -- Millipore Corporation (NYSE:MIL), a life science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today opened a new membrane casting manufacturing facility in Carrigtwohill, County Cork, Ireland. The 30,000 square foot facility...; Articles 2008-10-07
Biovest Announces BiovaxID® Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%: * Company Closes Phase 3 Fast-Tracked Clinical Trial * Will Petition to Offer All Study Patients Treatment with BiovaxID * Intends to Seek Approval in the U.S. and Internationally TAMPA, Fla. -- Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI),...; Articles 2008-10-07

<< Previous
page 1 of 1
Next >>

Content Types

Discussion threads (1 results)

Research articles (1 results)

Resources

biopharmaceutical

BNET Resources

Additional Resources

Content Types

Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors